Corporate news

FDA approves Grifols Prolastin®-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. The new formulation marks an important milestone in Grifols' ongoing R&D efforts
+ info

Grifols research lines in Alzheimer's move forward with both treatment and prevention Grifols has been supporting Alzheimer's research since 2004
+ info


Highlights

Manufacturing

Manufacturing
We are a solid company with an international dimension.

Corporate Commitment

People
We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.

When a Dream Comes True. An Illustrated History of 75 Years of Grifols

Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company.  + info

 

get to know us better